REC Ref	IRAS No	Name of Trial	First	Date of	Duration	Duration	Duration	Benchmark	Data Sita	Date Site	HRA	Date Site	Date Site	Non-
REC REI	IKAS NU		Patient		between	between	between		Invited	Selected	Approval	Confirmed	Confirmed	Confirmatio
			Recruited?		Date Site	Date Site	Date Site	linee	livited	Sciected	Date	By Sponsor	commed	n Status
			neer ance.	Recruited	Selected	Confirmed	Selected				Dute	by sponsor		il Status
					and Date	and First	and First							
					Site	Patient	Patient							
						Recruited	Recruited							
17/EE/0097	186866	A Phase I Open-Labelled Trial investigating immunisation	Yes	09/03/2018	6	177		No	16/01/2017	07/09/2017	07/09/2017	16/01/2017	13/09/2017	
		strategies using Ad4, MVA and rpg140 combinations in order to											, ,	
		maximise antibody responses												
17/EE/0330			Yes	26/09/2017	8	1	g	No	17/09/2017	17/09/2017	22/09/2017	25/09/2017	25/09/2017	
		Observational Study to Evaluate the Clinical Outcome of Ceramic-												
		on-Ceramic Hip Resurfacing Arthroplasty Using the H1 hip joint												
		ceramic non-porous non-cemented prosthesis												
17/SC/0411	217829	A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-	No		261			No	01/06/2016	23/08/2017	16/04/2018	20/03/2018	11/05/2018	
		CONTROLLED PHASE 3 STUDY OF VGX-3100X (DNA PLASMID												
		VECTORS EXPRESSING HPV-16 E6/E7, HPV-18 E6/E7) DELIVERED												
		intramuscularly FOLLOWED BY EP WITH CELLECTRA? 5PSP FOR												
		THE TREATMENT OF HISTOLOGICALLY PROVEN CIN2 OR CIN3												
		ASSOCIATED WITH HPV-16 AND/OR HPV-18												
15/NW/0545	156861		No		6	5		Yes	15/09/2016	19/04/2018	15/06/2016	15/09/2016	25/04/2018	
		trial comparing clinical outcomes in adults who receive												
		dexamethasone alongside standard treatment versus standard												
		treatment alone for Herpes Simplex Virus encephalitis.												
16/LO/1979		-	Yes	19/03/2018	9	192	201	No	04/01/2017	30/08/2017	20/12/2016	06/09/2017	08/09/2017	
		Therapy in high risk Apparent sTage 1 Endometrial Cancer							00/07/2017	46/04/2040			24/05/2040	
17/LO/0457			No		35					16/04/2018			21/05/2018	
16/EM/0436		SINGLE ARM, STUDY OF ALXN1210 IN COMPLEMENT INHIBITOR TREATMENT-NAIVE ADULT AND ADOLESCENT PATIENTS WITH	No		23			No	16/08/2017	16/08/2017	07/12/2016	16/08/2017	08/09/2017	
		ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS)												
17/LO/1991			Yes	30/01/2018)	41	/3	No	30/10/2017	18/12/2017	18/12/2017	30/10/2017	20/12/2017	
17/10/1991	172900	effect on the metabolic profiles of:	163	50/01/2018	2	41			50/10/2017	10/12/2017	10/12/2017	50/10/2017	20/12/2017	
		i) Healthy overweight and obese individuals												
		ii) Overweight and obese breast cancer follow-up patients												
18/SW/0103		A phase II prospective randomised clinical study of endoscopic	No		51			No	26/03/2018	11/04/2018	31/05/2018	11/04/2018	01/06/2018	
		ultrasound guided radiofrequency ablation (EUS-RFA) for												
		inoperable ductal pancreatic carcinoma												
17/EE/0079	220827	A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to	Yes	23/01/2018	92	0	92	No	20/02/2017	23/10/2017	06/04/2017	20/02/2017	23/01/2018	
		Evaluate the Safety and Efficacy of CCX168												
		(Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody												
		(ANCA)-Associated Vasculitis Treated Concomitantly												
		with Rituximab or Cyclophosphamide/Azathioprine												
16/NS/0094	206213	BioImpedance Spectroscopy to Maintain Renal Output: The	Yes	10/11/2017	65	30	95	No	23/02/2017	07/08/2017	04/10/2016	23/02/2017	11/10/2017	
		BISTRO Trial												
17/LO/0566	218514	An experimental medicine study to validate The 18 kD	No		25			No	17/03/2017	11/01/2018	19/12/2017	17/03/2017	05/02/2018]
		Translocator Protein as a novel neuroimmunodulatory target												
17/LO/0746		In comparison to usual care alone, does an adjunctive pre-surgery	No		1			Yes	20/02/2017	08/08/2017	01/08/2017	08/08/2017	09/08/2017	
		dietetic service improve the post-surgical nutritional outcomes for												
		patients with pancreatic cancer? A pilot study												

17/LO/0862	195365	The effects of fruits and vegetables on vascular function in prehypertensive participants: a pilot study	Yes	13/09/2017	2	53	55	No	21/04/2017	20/07/2017	04/07/2017	21/04/2017	22/07/2017
17/LO/0783			No		40			No	06/04/2017	24/08/2017	24/08/2017	25/09/2017	03/10/2017
17/SC/0291		The DEFINE PCI study: Physiologic assessment of coronary stenosis following PCI.	Yes	13/02/2018	139	63	202	No	09/03/2017	26/07/2017	29/08/2017	04/12/2017	12/12/2017
17/EM/0241		Safety and efficacy analysis of FRED/FRED Jr embolic device in aneurysm treatment	Yes	23/11/2017	62	65	127	No	05/07/2017	19/07/2017	08/08/2017	18/09/2017	19/09/2017
16/EE/0463		An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease.	Yes	20/10/2017	71	28	99	No	12/06/2017	13/07/2017	30/01/2017	18/09/2017	22/09/2017
17/LO/1169		Efficacy and usability of Ostom-i device in patients with ileostomy. A pilot study	No		1			No	25/09/2017	22/11/2017	20/10/2017		23/11/2017
17/NW/0254		A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy	Yes	27/11/2017	85	46	131	Yes	05/05/2017	19/07/2017	17/07/2017	25/09/2017	12/10/2017
17/LO/0939		Patient Empowerment Through Predictive Personalised Decision Support (PEPPER)	Yes	09/01/2018	35	22	57	No	12/09/2017	13/11/2017	08/11/2017	12/09/2017	18/12/2017
17/ES/0051		CANC 33870: A Phase II Open-Label Study of NUC-1031 in Patients with Platinum-Resistant Ovarian Cancer	Yes	19/01/2018	131	66	197	Within 70 [Da 07/06/2017	06/07/2017	05/07/2017		14/11/2017
17/LO/1095		Investigation of the metabolic effects of duodenal resurfacing on insulin resistant women with polycystic ovarian syndrome	Yes	11/04/2018	39	22	61	No	09/06/2017	09/02/2018	04/09/2017	09/06/2017	20/03/2018
17/EE/0264		A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non-Small- Cell Lung Cancer (NSCLC) (POSEIDON)	Yes	15/01/2018	75	49	124	Yes	02/06/2017	13/09/2017	12/09/2017	20/11/2017	27/11/2017
17/EE/0177		A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM).	Yes	03/10/2017	63	7	70	No	31/05/2017	25/07/2017	24/07/2017	18/09/2017	26/09/2017
17/SC/0554		A Phase III, multicenter, randomized controlled study to compare safety and efficacy of a haploidentical HSCT and adjunctive treatment with ATIR101, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells, versus a haploidentical HSCT with post-transplant cyclophosphamide in patients with a hematologic malignancy (HATCY study).	No		188			No	31/05/2017	10/10/2017	23/02/2018	21/03/2018	16/04/2018
16/WA/0156	204506	Minimally invasive thoracoscopically-guided right minithoracotomy versus conventional sternotomy for mitral valve repair: a multicentre randomised controlled trial (UK Mini Mitral).	Yes	13/03/2018	205	26	231	No	14/06/2017	25/07/2017	19/06/2016	31/01/2018	15/02/2018

17/LO/1590	229278	A Phase III, Randomized, Double-Blind, Clinical Trial of	No		121			Yes	11/07/2017	01/11/2017	27/10/2017		02/03/2018	
		Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects with Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585).												
17/LO/1441	219916	SYNCope EDUcation for patients during tilt-table tests	Yes	20/03/2018	26	36	62	Yes	02/08/2017	17/01/2018	12/09/2017		12/02/2018	
16/LO/0592	179775	Phase III randomised trial of immunomodulatory therapy in high risk solitary bone plasmacytoma	No					No	23/05/2017	30/08/2017	09/08/2016			Site declined
17/LO/1457	2277777	Randomised controlled trial of mechanochemical ablation versus cyanoacrylate adhesive for the treatment of varicose veins	Yes	06/11/2017	9	5	14	No	01/08/2017	23/10/2017	19/09/2017	30/10/2017	01/11/2017	
17/LO/1447	226100	The effectiveness of a focused point-of-care duplex ultrasound scan as a bedside screening tool to detect peripheral arterial disease in diabetes.	No		60			No	30/08/2017	06/11/2017	21/12/2017	15/12/2017	05/01/2018	
17/WS/0192	216416	Randomised controlled trial of foam sclerotherapy versus ambulatory phlebectomy for the treatment of varicose vein tributaries	Yes	22/01/2018	38	61	99	No	21/08/2017	15/10/2017	15/10/2017		22/11/2017	
17/LO/1247	228533	RANDOMIZED, OPEN LABEL, MULTICENTRE, PHASE 3 STUDY OF ROVALPITUZUMAB TESIRINE COMPARED WITH TOPOTECAN FOR SUBJECTS WITH ADVANCED OR METASTIC DLL3 SMALL CELL LUNG CANCER (SCLC) WHO HAVE FIRST DISEASE PROGRESSION DURING OR FOLLOWING FRONT LINE PLATINUM -BASED CHEMOTHERAPY	No		164			Yes	30/01/2017	22/08/2017	15/08/2017		02/02/2018	
17/LO/1040	226283	p53 Suppressor Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Phase II Study of Systemic Pegylated Liposomal Doxorubicin Chemotherapy With APR-246	Yes	17/11/2017	1	31	32	No		16/10/2017	04/09/2017		17/10/2017	
17/YH/0311	229294	A Modular, Multipart, Multiarm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malignancies	Yes	28/11/2017	79	4	83	No	29/08/2017	06/09/2017	30/10/2017		24/11/2017	
17/WS/0180	225790	A Phase 111b, Randomised, Double-blind, Placebocontrolled, MulticentreStudy of Olaparib Maintenance Retreatment in Patients with EpithelialOvarian Cancer Previously Treated With a PARPi and Responding toRepeat Platinum Chemotherapy (OReO)	No		174			No	11/09/2017	13/10/2017	02/02/2018		05/04/2018	
17/EE/0340	213113	INTERIM: a randomised phase II feasibility study of INTERmittent versus continuous dosing of oral targeted combination therapy (BRAF+ MEKi) in patients with BRAFV600 mutant stage 3 unresectable or metastatic Melanoma.	No		82			No	01/08/2017	25/10/2017	15/10/2017	03/01/2018	15/01/2018	
17/SC/0394	229032	An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib.	Yes	19/12/2017	101	26	127	No	07/08/2017	14/08/2017	23/10/2017	22/11/2017	23/11/2017	
17/LO/1149	220763	A Phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study to assess the efficacy and safety of maribavir compared to valganciclovir for the treatment of cytomegalovirus (CMV) infection in hematopoietic stem cell transplant recipients.	No		194			No	26/07/2017	26/07/2017	12/09/2017	09/10/2017	05/02/2018	

[
17/EM/0338	229242		No		93			Within 70 Da	04/09/2017	07/02/2018	31/01/2018	04/05/2018	11/05/2018	
		ABL001 versus bosutinib in patients with Chronic Myelogenous												
		Leukemia in chronic phase (CML-CP), previously treated with 2 or												
		more tyrosine kinase inhibitors												
17/LO/1320	229845	Single-arm, phase II study of Luspatercept (ACE-536) in anemic	No		153			No	10/08/2017	10/08/2017	27/10/2017	22/12/2017	10/01/2018	
		patients with MPN-associated myelofibrosis.												
17/SC/0408	228262	A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of	No		200			No	18/09/2017	18/09/2017	19/09/2017	06/04/2018	06/04/2018	
		Itacitinib or Placebo in Combination with Corticosteroids for the												
		Treatment of First-Line Acute Graft-Versus-Host Disease.												
17/LO/1429	223671	A Two-Part Phase 1/2 Study to Determine Safety, Tolerability,	No		191			No	06/09/2017	06/09/2017	29/01/2018	12/01/2018	16/03/2018	
		Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase												
		Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic												
		Myeloid Leukemia (CML) or Philadelphia Chromosome Positive												
		Acute Lymphoblastic Leukemia (Ph+ ALL).												
17/LO/1847	216867	A randomised phase II trial of Selinexor, cyclophosphamide and	No		90			Within 70 Da	22/11/2017	14/02/2018	04/01/2018	11/03/2018	15/05/2018	
		prednisone vs cyclophosphamide and prednisone in relapsed or												
		refractory multiple myeloma (RRMM) patients.												
17/LO/1500	224823	A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-	No		136			Within 70 Da	05/02/2018	13/02/2018	06/03/2018	10/09/2017	29/06/2018	
		controlled Study of AG-120 in Combination with Azacitidine in												
		Subjects = 18 Years of Age with Previously Untreated Acute												
		Myeloid Leukemia with an IDH1 Mutation Who are candidates for												
		Non-intensive Therapy.												
17/SC/0201	209172	Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover	Yes	23/05/2018	55	7	62	Within 70 Da	29/01/2018	22/03/2018	18/10/2017	07/05/2018	16/05/2018	
		Study.												
16/SC/0200	202397	Proof-of-concept trial on selective removal of the anti-angiogenic	No					Within 70 Da	18/09/2017	23/05/2018				
		factor soluble fms-like tyrosine kinase-1 (sFlt-1) in pregnant												
		women with pre-eclampsia via apheresis utilising the Flt-1												
		adsorption column												
17/EM/0371	229496	Strategic Management to Optimize Response To Cardiac	Yes	29/05/2018	30	34	64	No	10/07/2017	26/03/2018	21/11/2017	19/04/2018	25/04/2018	
		Resynchronization Therapy												
17/NE/0331	229957	A prospective, global, multicentre, real world outcome study of	Yes	18/04/2018	55	63	118	Within 70 Da	05/06/2017	21/12/2017	20/12/2017	14/02/2018	14/02/2018	
		fenestrated endovascular aneurysm repair using the fenestrated												
		Anaconda (TM) device												
18/LO/0217	235711	INvestigational Study Into Transplantation of the Uterus (INSITU)	No		32			Yes	24/01/2018	23/04/2018	28/02/2018	25/05/2018	25/05/2018	
17/LO/1695	234684	A Phase 3 Open-Label, Single-Arm Study To Evaluate The Efficacy	No		65			No	09/10/2017	09/10/2017	24/11/2017		13/12/2017	
		and Safety of BMN 270, an Adeno-Associated Virus Vector-												
		Medicated Gene Transfer of Human Factor VIII in Haemphilia A												
		Patients with Residual FVIII Levels 1 IU/dl Receiving Prophylactic												
		FVIII Infusions.												
16/EM/0382	210424	A multicenter, randomized, double-blind, active-controlled study	No		40			No	12/10/2017	23/02/2018	05/12/2016	08/02/2018	04/04/2018	
		to evaluate the effects of LCZ696 compared to valsartan on												
		cognitive function in patients with chronic heart failure and												
		preserved ejection fraction.												
17/LO/1918	229435	Does Neuromuscular Electrical Stimulation Improve the Absolute	Yes	08/03/2018	45	20	65	No	09/11/2017	02/01/2018	29/01/2018		16/02/2018	
		Walking Distance in Patients with Intermittent Claudication												
		(NESIC) compared to best available treatment? A Multicentre												
		Randomised Controlled Study												
17/LO/1592	225931	AN OPEN-LABEL, MULTICENTER EXTENSION STUDY IN PATIENTS	Yes	02/01/2018	89	15	104	No	15/09/2017	20/09/2017	07/11/2017	12/12/2017	18/12/2017	
		PREVIOUSLY ENROLLED IN A GENENTECH- AND/OR F. HOFFMANN-												

17/NE/01E1	222015	Phase 2 Multicenter Dendemized Open Label Study of	No	T T	125			Within 70 D	01/11/2017	01/11/2017	10/07/2017	07/03/2018	16/02/2010	
17/NE/0151	223813	Phase 3, Multicenter, Randomized, Open-Label Study of	No		135				01/11/2017	01/11/201/	19/0//201/	07/03/2018	10/03/2018	
		Guadecitabine (SGI-110) versus Treatment Choice in Adults with												
17/10/1020	222005	Previously Treated Acute Myeloid Leukemia (SGI-110-06).	No	+ +	140			Ne	02/11/2017	12/11/2017	05/02/2010	27/02/2010	10/04/2010	
17/LO/1929	233885		INO		148			No	02/11/2017	13/11/2017	05/02/2018	27/03/2018	10/04/2018	Sponsor decl
		Efficacy and Safety of Pembrolizumab plus Epacadostat,												
		Pembrolizumab, and the EXTREME Regimen as First line												
		Treatment for Recurrent or Metastatic Head and Neck Squamous												
17/55/0401	226442	Cell Carcinoma (KEYNOTE-669/ECHO-304)	No	+	74			Ne	00/11/2017	24/11/2017	05/01/2019	00/11/2017	00/02/2010	,
17/EE/0481		Pre-Implantation trial of Histopathology In renal Allografts	No		74			No				08/11/2017		
18/LO/0196	23/129	, ,	No		16			within 70 Da	10/01/2018	27/02/2018			15/03/2018	5
47/115/0000	225047	Subcutaneous Insulin Infusion (CSII) in Adults with Type 1 Diabetes							00/11/2017	00/05/0040	24/40/2047	20/05/2040	20/05/2040	
17/NE/0300	22591/	A phase II, randomised, double-blind, placebo-controlled, parallel-	Yes	04/07/2018	22	35	57	NO	06/11/2017	08/05/2018	31/10/201/	30/05/2018	30/05/2018	5
		group, multicentre study investigating the efficacy												
		and safety of Sepranolone (UC1010) in patients with PMDD		+ +									/ /	
17/LO/0118	220143	Maternal Moments: Investigating music listening of well-being in	No		7			No	03/11/2017	14/12/2017	28/04/2017	14/12/2017	21/12/2017	<i>′</i>
		pregnancy		+ +										
17/NW/0351	224954	A phase II single arm clinical trial of a Tailored ImmunoTherapy	No					Site Not Con	firmed	12/09/2017				
		Approach with Nivolumab in subjects with metastatic or advanced												
		Renal Cell Carcinoma											/ /	
17/EE/0368	213669	, , , , , , , , , , , , , , , , , , , ,	Yes	03/07/2018	37	60	97	No	12/10/2017	28/03/2018	10/11/2017	12/03/2018	04/05/2018	3
/		(Beta Blockade)		+ +									/ /	
17/EE/0498	239464	Pain relief with disease modification by Capsaicin 8% patch: a	No		114			Within 70 Da	28/11/2017	12/03/2018	12/03/2018	04/07/2018	04/07/2018	5
		clinical study in Diabetic Peripheral Neuropathy		+ +										
17/EE/0480	235288	A Phase 3 Randomized, Double-Blind Trial of Pembrolizumab (MK-	No		117			No	27/11/2017	14/12/2017	05/02/2018	27/03/2018	10/04/2018	Sponsor decl
		3475) in Combination with Epacadostat (INCB024360) or Placebo												
		in Participants with Cisplatin-ineligible Urothelial Carcinoma												
		(KEYNOTE-672/ECHO-307)												
17/LO/2059	235808	A Phase 3 Randomized, Double-Blind Clinical Study of	No		103			No	27/11/2017	14/12/2017	29/01/2018	20/03/2018	27/03/2018	Sponsor decl
		Pembrolizumab +												
		Epacadostat vs Pembrolizumab + Placebo as a Treatment for												
		Recurrent or Progressive Metastatic												
		Urothelial Carcinoma in Patients who have Failed a First-Line												
		Platinum-containing												
		Chemotherapy Regimen for Advanced/Metastatic Disease												
		(KEYNOTE-698/ECHO-303)												
17/SC/0641	238111	A Phase 1/2 Safety, Tolerability, and Efficacy Study of BMN 270, an	No					No	08/12/2017	08/12/2017				Sponsor decl
		Adeno-Associated Virus Vector?Mediated Gene Transfer of												
		Human Factor VIII in Hemophilia A Patients with Residual FVIII												
		Levels = 1 IU/dL and Pre-existing Antibodies Against AAV5												
18/WM/0022		AG-348 in Regularly Transfused Adult Subjects with PK Deficiency			117			Yes			11/04/2018		16/05/2018	
18/LO/0054	236047		Yes	30/04/2018	14	26	40	Yes	06/07/2017	21/03/2018	14/02/2018	06/07/2017	04/04/2018	3
		human interstitial fluid												
17/LO/0103	216784	A Multicenter, Double-Blind, Double-Dummy Study to Explore the	No		15			No	20/06/2017	20/12/2017	05/07/2017		04/01/2018	3
		Long-Term Safety of TEV-48125 for the Prevention of Cluster												
	_	Headache												ļ
17/LO/0102	215259	A Multicenter, Randomized, Double-Blind, Double-Dummy,	No		11			No	12/12/2016	22/12/2017	14/07/2017	12/12/2016	02/01/2018	3
		Placebo-Controlled, Parallel-Group Study Comparing the Efficacy												
		and Safety of 2 Dose Regimens (Intravenous/ Subcutaneous and												
		Subcutaneous) of TEV-48125 versus Placebo for the Prevention of												
		CHRONIC Cluster Headaches (CCH)												

17/LO/0742	219709	A randomised controlled comparison of effectiveness of facemask pre-oxygenation and Transanal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) in bariatric patients undergoing	No		3			No	15/02/2017	10/07/2017	29/06/2017	13/07/2017	13/07/2017
16/WM/0285		general anesthesia A Double Blind, Randomized, Placebo Controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy on LDL-C of Evolocumab (AMG 145) in Subjects with HIV and with Hyperlipidemia and/or Mixed Dyslipidemia	Yes	01/08/2017	16	12	28	No	17/03/2017	04/07/2017	22/06/2017	17/03/2017	20/07/2017
17/LO/1003	206965	Perforated Punctal Plug as an alternative to the three snip punctoplasty for the treatment of acquired lacrimal punctum stenosis	Yes	04/09/2017	0	24	24	No	22/03/2017	11/08/2017	01/08/2017	11/08/2017	11/08/2017
17/NE/0181	220972	Feasibility study for the use of intraoperative single dose radiotherapy for locally advanced and recurrent pelvic cancer	No		12			No	20/04/2017	05/10/2017	06/09/2017		17/10/2017
17/LO/0095	216048	A tailored, cognitive behavioural approach intervention for mild to moderate anxiety and/or depression in people with chronic obstructive pulmonary disease (COPD): A randomised controlled trial.	Yes	31/10/2017	17	96	113	Yes	07/04/2017	10/07/2017	08/03/2017	07/04/2017	27/07/2017
16/NW/0877		A Safety and Tolerability Study of LY3303560 in Alzheimer's Disease	Yes	06/10/2017	6	66	72	No	19/04/2017	26/07/2017	05/04/2017	19/04/2017	01/08/2017
16/SS/0137	199347	Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis 2	Yes	14/06/2018	129	90	219	No	24/04/2017	07/11/2017	11/01/2017	24/04/2017	16/03/2018
17/WM/0425		A phase III trial evaluating the efficacy and safety of the SQ house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet in children and adolescents with HDM allergic asthma		04/04/2018	55	76	131					18/01/2018	
16/SC/0338	191612	Prospective Interruption of Therapy towards a Cure for HIV (PITCH) Pilot Study	No		196		,	Yes	09/05/2017	09/08/2017	22/11/2016	17/10/2017	21/02/2018
16/YH/0157	204585	PLATO - PersonaLising Anal cancer radioTherapy dOse - Incorporating Anal Cancer Trials (ACT) ACT3, ACT4 and ACT5	Yes	22/03/2018	128	69	197	No	26/08/2016	06/09/2017	20/07/2016		12/01/2018
17/LO/1129	226325	An adaptive orthosis for hand osteoarthritis; feasibility and prototype	Yes	04/10/2017	7	20	27	Yes	08/09/2017	07/09/2017	07/09/2017	08/09/2017	14/09/2017
16/SW/0120		Study of the optimum duration of acoustic pulse thrombolysis procedure in the treatment of acute submassive pulmonary embolism	No		228			No	31/05/2017	03/08/2017	04/10/2016	19/03/2018	19/03/2018
17/LO/0525	221541	A prospective, double-masked, randomized, multicenter, active- controlled, parallel-group, 6-month study assessing the safety and ocular hypotensive efficacy of PG324 Ophthalmic Solution compared to GANFORT? (bimatoprost 0.03%/timolol 0.5%) Ophthalmic Solution in subjects with elevated intraocular pressure (MERCURY 3).			37			Within 70 Da	05/12/2016	25/10/2017	30/06/2017	30/11/2017	01/12/2017
17/LO/0848	222163	A Phase 3, Randomized, Double-Blind, Placebo-Controlled StudyEvaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis	Yes	01/02/2018	42	71	113	No	18/04/2017	11/10/2017	02/08/2017		22/11/2017
17/LO/0849	222165	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)-STELLAR 4	Yes	04/12/2017	43	11	54	No	31/08/2017	11/10/2017	02/08/2017		23/11/2017
17/WM/0146	220303	A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer?s Disease	No		3			Site Not Con	23/05/2017	30/04/2018	21/08/2017	23/05/2017	03/05/2018

17/514/0154	222012 A Multi centre Deuble blind Deudemized Discobe centrelled	Vaa	02/02/2010	4	115	110	Ne	00/00/2017	00/10/2017	27/06/2017	00/00/2017	10/10/2017	
17/EM/0154		Yes	02/02/2018	4	115	119	NO	08/06/2017	06/10/2017	27/06/2017	08/06/2017	10/10/2017	
	Parallel-arm Phase IIa Trial to Evaluate the Efficacy,												
	Safety and Tolerability of 28-Day Oral Treatment with PXT002331												
	(foliglurax) in Reducing Motor Complications of												
	Levodopa Therapy in Subjects with Parkinson?s Disease												
	Experiencing End-of-dose Wearing Off and Levodopa-												
	Induced Dyskinesia (AMBLED)												
17/LO/0719	o , , , ,	Yes	16/10/2017	31	/	38	Yes	20/06/2017	08/09/2017	20/06/2017	04/10/2017	09/10/201/	
	multiple doses of live attenuated influenza vaccine (LAIV)												
	compared to influenza vaccine-na?ve controls		+ +									10/10/00/7	
17/EM/0236	221138 Dose finding phase IIb study of Bavisant to evaluate its safety and	No		0			Within 70 D	a 19/06/2017	18/12/2017	08/08/2017	19/06/2017	18/12/2017	
	effiCacy												
	in treAtment of exceSsive daytime sleePiness (EDS) in PARkinson's												
	Disease												
10/10/0001	(PD).		+							10/00/00/0			
18/LO/0091	140718 Side-Stream Dark Field video analysis of cerebral microcirculation	NO		32			Yes	12/12/2017	12/02/2018	12/02/2018		16/03/2018	
	in patients with traumatic brain injury or a brain tumour: the												
1 - 1 - 1 - 2 - 2 - 2	effects of blood pressure and intracranial pressure		+ +							07/00/00/7			
17/YH/0296		No					Within 70 D	04/08/2017	16/10/2017	2//09/201/			
47/10/4202	through wearable sensors and digital alerting.		42/42/2047	25		74		42/07/2047	00/00/0047	05/00/0047	07/00/0047	07/00/0047	
17/LO/1390	3	Yes	13/10/2017	35	36	/1	Yes	12/0//201/	03/08/2017	05/09/201/	07/09/2017	07/09/2017	
	they attend emergency or urgent care with a child under 5 years												
	old in non-urgent situation, in order to reduce future repeat non-												
47/10/4004	urgent attendances							00/07/0047	24/00/2047	24/22/2247			
17/LO/1091	229631 A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of the	NO					No	03/07/2017	24/08/2017	24/08/2017			Sponsor dec
	Combination Regimen of MK-3682B												
	(Grazoprevir/Ruzasvir/Uprifosbuvir) in Participants with Chronic												
47/00050	Hepatitis C Virus Genotype 3 Infection	N1 -		450				02/07/2017	05/10/2017	40/00/2047	20/42/2047	12/02/2010	
17/NW/0352	226135 Resuscitative Endovascular Balloon Occlusion of the Aorta for Trauma	No		159			Within 70 D	a 03/07/2017	05/10/2017	10/08/2017	20/12/2017	13/03/2018	
17/EM/0301		Yes	05/02/2018	16	46	62	No	13/07/2017	05/12/2017	29/09/2017	20/12/2017	21/12/2017	
17/EE/0387		No		0				30/08/2017					
17/LO/1568		Yes	16/12/2017	26	38			30/08/2017					
	Teenagers - does dose matter?									, ,		, ,	
	The PIMAT study												
18/LO/0745	231612 IL-1 Signal Inhibition in Alcoholic Hepatitis (Isaiah)	No					Within 70 D	05/04/2018	27/06/2018	11/07/2018			
17/YH/0329	216857 A randomized, double-blind, placebo-controlled, two-cohort	No		38			No	31/07/2017	14/05/2018	28/11/2017	31/07/2017	21/06/2018	
	parallel group study to evaluate the efficacy of CAD106 and												
	CNP520 in participants at risk for the onset of												
	clinical symptoms of Alzheimer?s disease												
17/LO/1245		Yes	08/03/2018	25	31	56	No	11/09/2017	11/01/2018	10/11/2017	11/09/2017	05/02/2018	
	effectiveness of topical lactic acid gel for treating second												
	and subsequent episodes of bacterial vaginosis												
17/EE/0026		Yes	05/01/2018	69	85	154	Within 70 D	15/02/2017	04/08/2017	19/06/2017	21/09/2017	12/10/2017	
	Study of the ACRYSOF IQ Extended Depth of Focus (EDF) IOL												
17/EM/0361	234065 A Multicenter, Randomized, Double-Blind, Placebo-Controlled	No		14			No	20/09/2017	28/02/2018	11/01/2018	20/09/2017	14/03/2018	
	Study in Subjects With Relapsing Multiple Sclerosis to												
	Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy												
	to Anti-Inflammatory Disease-Modifying Therapies												
	(AFFINITY)							1					

17/SC/0658	232220	SABRE- Serratus Anterior Block and catheter use in Rib fractures in	No					Within 70 Da	15/11/2017	12/06/2018				
		the Emergency department												
17/LO/1693	233988	A multicenter, randomized, double-blind, placebo controlled, parallel group clinical study investigating the efficacy, tolerability, and safety of two dosing regimens of continuous subcutaneous ND0612 infusion Given as adjunct treatment to oral levOdopa in patients with Parkinson?s Disease	No					Within 70 Da	04/10/2017	10/04/2018		04/10/2017		
16/LO/0831	106728	with motor fluctuations (iNDiGO) Efficacy, safety and impact on antimicrobial resistance of duration	No	+ +	133			Within 70 D	20/06/2017	26/10/2017	11/11/2016	08/03/2018	08/02/2018	
10/10/0831		and dose of amoxicillin treatment with Community-Acquired Pneumonia (CAP): a randomised controlled trial	NO		155				20/00/2017	20/10/2017	11/11/2010	00/03/2018	00/03/2010	
17/LO/0380		PET-LONGITUDINAL SUBSTUDY ASSOCIATED WITH: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED,PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER?S DISEASE	No		0			Within 70 Da	25/01/2018	25/01/2018	18/05/2017	25/01/2018	25/01/2018	
17/SC/0582	234404		No		156			Within 70 Da	24/10/2017	24/01/2018	18/01/2018	27/06/2018	29/06/2018	
16/LO/0680	186642		No		39			Within 70 Da	08/11/2017	29/01/2018	28/07/2016	09/03/2018	09/03/2018	
18/EE/005	232671		No						10/11/2017	23/05/2018				
17/LO/1478	226023		Yes	08/03/2018	64	14	78		22/09/2017	20/12/2017	23/11/2017	22/09/2017	22/02/2018	
17/EE/0474		The open-label, randomised, multi-centre, parallel group, two-arm study to assess the safety, overall tolerability, and antiviral activity of Brincidofovir versus standard of care for treatment of adenovirus infections in high-risk paediatric allogeneic haematopoietic cell transplant recipients		10/04/2018	23	67	90		14/07/2017	10/01/2018	05/01/2018	02/02/2018	02/02/2018	
18/LO/0314			No		14					28/03/2018	06/04/2018		11/04/2018	
18/LO/0700		A Phase 1/2 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in Subjects with Transfusion- Dependent ? Thalassemia.	No						10/04/2018	18/05/2018	02/07/2018			
18/LO/0270		Can NIRS be used as an intra-operative monitor of spinal cord function and predict patient outcome after vascular surgery?	No		31					17/04/2018			18/05/2018	

17/00/0000	226242	A Disco 2 Open Label single Arm Children Frederic The Sff	N	, , , , , , , , , , , , , , , , , , ,			I	00/04/2010	45/04/2042	26/02/2010	22/02/2010	05/04/2042	
17/SC/0639	236312		No		80			09/01/2018	15/01/2018	26/02/2018	22/03/2018	05/04/2018	
		and Safety of BMN 270, an Adeno-Associated Virus Vector-											
		Mediated Gene Transfer of Human Factor VIII at a dose of 4E13											
		vg/kg in Haemophila A Patients with Residual FVIII Levels 1 IU/dL											
		Receiving Prophylactic FVIII Infusions											
18/LO/0070	238482		No		24			23/01/2018	30/04/2018	30/04/2018	10/05/2018	24/05/2018	
		Refractory Dyskinesis Symptoms or Motor Fluctuations of											
		Advanced Idiopathic Parkinson?s Disease With Unilateral											
		Lesioning of the Globus Pallidum Using the ExAblate Neuro System											
40/0007	244024		NL -					02/05/2010	45/05/2040	10/00/0010			
18/WS/0087	241031	Optimal duration of Cooling therapy in Mild Encephalopathy (COMET 1)	No					02/05/2018	15/05/2018	18/06/2018			
17/EM/0412	234907	An adaptive seamless randomized, double-blind,	No		7			15/01/2018	01/05/2018	04/12/2017		08/05/2018	
1,7 2101,0 112	231507	placebocontrolled, dose ranging study to investigate the efficacy			,			10/01/2010	01,03,2010	01,12,201,		00,00,2010	
		and safety of LNP023 in primary IgA nephropathy patients											
18/LO/0666	2/12700		No	<u> </u>				11/04/2018	22/05/2018	15/05/2018	13/07/2018		
10, 10, 0000	272/00	Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential							22/03/2010	13/03/2010	13/07/2010		
		Thrombocythemia Myelofibrosis (Post-PV/ET MF).											
18/LO/0170	236855	A Phase III, Randomized, Open-label Study to Evaluate	No					29/01/2018	26/03/2018				
		Pembrolizumab as Neoadjuvant Therapy and in combination with											
		Standard of Care as Adjuvant Therapy for Stage III-IVB Resectable											
		Locoregionally Advanced Head and Neck Squamous Cell											
		Carcinoma (HNSCC)											
18/NW/0031	230387		No					12/02/2018	12/02/2018	08/02/2018			
10,111,0001	200007	single-stage						12,02,2010	12, 02, 2010	00,02,2010			
		selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil											
		(5-FU)/folinic acid or docetaxel as second-line therapy in patients											
		with											
		progressive poorly differentiated extra-pulmonary											
		neuroendocrine											
18/LO/0376	236553		Yes	16/05/2018	27	8	35	23/03/2018	11/04/2018	11/04/2018		08/05/2018	
18/NW/0107			No	10/03/2010	39				04/06/2018			13/07/2018	
10/10/010/	230034	cerebral ArterioVenous Malformation	110		55			20/02/2010	04,00,2010	14/03/2010		13/0//2010	
18/LO/0235	240315	An Open Label Extension Study of GBT440 Administered Orally to	No						20/06/2018	17/04/2018			
10/20/0200	210313	Patients with Sickle Cell Disease Who Have	110						20,00,2010	1770172010			
		Participated in GBT440 Clinical Trials											
18/LO/0512	196718	DICE Trial: An international multi-centre randomised phase II	No						12/06/2018	05/06/2018			
10/10/0512	150710	study to assess the efficacy of TAK228 in combination with	NO						12,00,2010	03/00/2010			
		intravenous weekly paclitaxel compared with weekly paclitaxel											
		alone in women with advanced/recurrent epithelial ovarian,											
		fallopian tube or primary peritoneal cancer (of clear cell,											
18/LO/0393	240055	endometrioid and high grade serous type, and carcinosarcoma)	No	┼───┤					21/06/2018				
10/10/0393	240955	A Phase I, Open-Label, Ascending Dose Study to Assess the Safety							21/00/2018				
		and Tolerability of AAV2/6 Factor IX Gene Therapy											
		via Zinc Finger Nuclease (ZFN) mediated targeted integration of SB-	1										
	204222	FIX in Subjects with Severe Haemophilia B		┥───┤				00/00/00:5	20/02/22/2	20/04/221-			
16/LO/2150	201093		No					20/03/2018	20/03/2018	26/01/2017			
		and cediranib in patients with BRCA mutated platinum?resistant											
		ovarian cancer											

18/SS/0010	238051 A Phase 3 Study of Erdafitinib Compared With Vinflunine or	No			05/02/2018	04/05/2018				
10, 33, 0010	Docetaxel or				00,02,2010	01,00,2010				
	Pembrolizumab in Subjects with Advanced Urothelial Cancer and									
	Selected FGFR Gene									
	Aberrations									
18/LO/0858	241447 A PHASE II, RANDOMIZED, ACTIVE-CONTROLLED, MULTI-CENTER	No				16/05/2018	12/07/2018			
	STUDY COMPARING THE EFFICACY AND SAFETY OF TARGETED									
	THERAPY OR CANCER IMMUNOTHERAPY GUIDED BY GENOMIC									
	PROFILING VERSUS PLATINUM-BASED CHEMOTHERAPY IN									
	PATIENTS WITH CANCER OF UNKNOWN PRIMARY SITE WHO HAVE									
	RECEIVED THREE CYCLES OF PLATINUM DOUBLET									
	CHEMOTHERAPY									
18/LO/0995	244737 A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare	No			13/04/2018	05/06/2018		09/03/2018		
	the Efficacy and Safety of Lenvatinib in Combination with									
	Pembrolizumab Versus Treatment of Physician?s Choice in									
	Participants with Advanced Endometrial Cancer									
18/NE/0136		No			02/05/2018	02/05/2018		13/02/2018		
	Nivolumab versus Placebo for Participants with Hepatocellular									
	Carcinoma Who Are at High Risk of Recurrence after Curative									
15 / 4/ 10200	Hepatic Resection or Ablation	NIa				25/05/2010	20/00/2010	12/07/2010		
15/WM/0268	180518 Randomised, open label study of Rituximab/Ibrutinib vs Rituximab/Chemotherapy in older patients with untreated mantle	No			25/05/2018	25/05/2018	26/08/2016	13/07/2018		
	cell lymphoma.									
18/YH/0097		No			29/05/2018	06/06/2018				
10/11/005/	study to evaluate the efficacy and safety of CNP520 in				23/03/2010	00/00/2018				
	participants at risk for the onset of clinical symptoms of									
	Alzheimer?s Disease (AD)									
17/WA/0420		No			14/06/2018	14/06/2018				
17/EM/0406		No				20/06/2018				
	Adult Patients with Persistent/Chronic Immune									
	Thrombocytopenia (PRTX-100-202)									
18/LO/1007	242697 Patient-Reported Outcomes with the Accu-Chek? Solo Micropump	No			12/06/2018	12/06/2018				
	System vs. Multiple Daily Injection Therapy vs. mylife OmniPod? in									
	Patients with Type 1 Diabetes									
17/EE/0382	° °	No				15/06/2018				
	Biomarker (PROFILE) Trial.									
18/LO/0565	241439 Early administration of anti-latency reversing therapy and broadly	No			12/04/2018	30/05/2018				
	neutralizing antibodies to limit the establishment of the HIV-1									
	reservoir during initiation of antiretroviral treatment - a									
	randomized controlled trial									
19/10/0709	(eCLEAR)	No			04/06/2019	11/00/2019				
18/LO/0798 18/NE/0142		No No				14/06/2018 30/05/2018				
10/ NE/ 0142	Multicenter Study to Evaluate the Efficacy and Safety of				04/03/2018	30/03/2018				
	Obeticholic Acid in Subjects with Compensated Cirrhosis due to									
	Nonalcoholic Steatohepatitis									
17/SC/0244	226900 A randomised, parallel-group, double-blind, double-dummy, active	No	49		09/05/2018	18/05/2018	27/07/2017	26/06/2018	06/07/2018	
,,	controlled, multicentre study to assess the efficacy and safety of	-			,	.,,	,, =•=,	.,,	-,, 	
	vilaprisan in subjects with uterine fibroids									
18/NE/0214		No		1 1	1	18/06/2018				

240879 A Prospective, Multicenter Clinical Trial Designed to Evaluate the	No				12/06/2018		
Safety and Effectiveness of the XEN45 Glaucoma Treatment							
System in Patients with Angle Closure Glaucoma.							

	В-	C - Closed			F - No		H-	I - Rare	J - Other	Reasons
ns	d by			availabilit y issues	patients seen	-		diseases		for delay correspon d to:
			Y							Sponsor
Y			Y			Y				Neither
						Y				Neither
						Y				Neither
						Y		v		Neither Neither
								1		Neither
Y										Neither
			Y							Sponsor
			Y							Sponsor
						Y				Neither
						Y				Neither
	Permissio ns delayed/d enied Y	Permissio Suspende delayed/d sponsor enied I Y I Y I I I <td>Permissio Suspende by delayed/d sponsor sponsor enied Image: Suspende of the sponsor Image: Suspende of the sponsor Y Image: Suspende of the sponsor Image: Suspende of the sponsor Y Image: Suspende of the sponsor Image: Suspende of the sponsor Y Image: Suspende of the sponsor Image: Suspende of the sponsor Y Image: Suspende of the sponsor Image: Suspende of the sponsor Y Image: Suspende of the sponsor Image: Suspende of the sponsor Y Image: Suspende of the sponsor Image: Suspende of the sponsor Y Image: Suspende of the sponsor Image: Suspende of the sponsor Y Image: Suspende of the sponsor Image: Suspende of the sponsor Y Image: Suspende of the sponsor Image: Suspende of the sponsor Y Image: Suspende of the sponsor Image: Suspende of the sponsor Y Image: Suspende of the sponsor Image: Suspende of the sponsor Y Image: Suspende of the sponsor Image: Suspende of the sponsor Y Image: Suspende of the sponsor Image: Suspende of the sponsor Image: Suspende of the sponsor <</td> <td>Permissio ns delayed/d sponsorSuspende dy sponsorby sponsorSponsor DelaysImage: sponsor eniedImage: sponsor sponsorImage: sponsor sponsorImage: sponsor DelaysImage: sponsor sponsorImage: sponsor sponsorImage: sponsor sponsorImage: sponsor DelaysImage: sponsor sponsorImage: sponsor sponsorImage: sponsor sponsorImage: sponsor sponsorImage: sponsor sponsorImage: sponsor sponsorImage: sponsor sponsorImage: sponsor sponsorImage: sponsor sponsorImage: sponsor sponsor sponsorImage: sponsor sponsorImage: sponsor sponsorImage: sponsor sponsorImage: sponsor sponsor sponsorImage: sponsor sponsorImage: sponsor sponsorImage: sponsor sponsorImage: sponsor sponsor sponsorImage: sponsor sponsorImage: sponsor sponsorImage: sponsor sponsorImage: sponsor sponsor sponsorImage: sponsor sponsorImage: sponsor sponsorImage: sponsor sponsorImage: sponsor sponsor sponsor sponsorImage: sponsor sponsor sponsorImage: sponsor sponsor sponsor sponsor sponsor sponsor sponsor spon</br></br></br></br></br></br></br></br></br></td> <td>Permission scale delayed/d eniedSuspende by sponsor pelaysSponsor availabilit y issuesImage: scale operationImage: scale pelaysImage: scale pelaysImage: scale pelaysImage: scale operationImage: scale pelaysImage: scale pelaysImage: scale pelaysImage: scale pelaysImage: scale pelaysImage: scale omerationImage: scale pelaysImage: scale pelaysImage: scale pelaysImage: scale pelaysImage: scale pelaysImage: scale omerationImage: scale pelaysImage: scale pelaysImage: scale pelays<!--</td--><td>Permissio ns delayed/d eniedSuspende by sponsorSponsor Delaysavailabilit y issuespatients seenImage: Image: Im</td><td>Permission schemed delayed/dSuspende sponsorSponsor Delaysavailabilit y issuespatients seenpatients consentedImage: sponsor eniedImage: sponsor sponsorYImage: sponsor sponsorImage: sponsor sponsorIm</td><td>Permissio ns delayed/dSuspende by sponsorSponsor Delaysavailabilit y issuespatients seenDatients consentedContracti ng delaysImage: sponsor eniedImage: sponsor patientsImage: sponsor sponsorImage: sponsor sponsor<td>Permissions Suspende delayed/, disponsor by sponsor availability susues patients seen Contract. diseases Image: Supponde enied Image: Supponsor Y Image: Supponsor Imag</td><td>Permission ns delayed/ disponsor by sponsor Sponsor Delays availabilit y issues patients consented Contracti ng delays diseases Image: sponsor V Image: sponsor V Image: sponsor No Image: sponsor No Image: sponsor Image: sponsor Image: sponsor V Image: sponsor V Image: sponsor Image: sponsor</td></td></td>	Permissio Suspende by delayed/d sponsor sponsor enied Image: Suspende of the sponsor Image: Suspende of the sponsor Y Image: Suspende of the sponsor Image: Suspende of the sponsor Y Image: Suspende of the sponsor Image: Suspende of the sponsor Y Image: Suspende of the sponsor Image: Suspende of the sponsor Y Image: Suspende of the sponsor Image: Suspende of the sponsor Y Image: Suspende of the sponsor Image: Suspende of the sponsor Y Image: Suspende of the sponsor Image: Suspende of the sponsor Y Image: Suspende of the sponsor Image: Suspende of the sponsor Y Image: Suspende of the sponsor Image: Suspende of the sponsor Y Image: Suspende of the sponsor Image: Suspende of the sponsor Y Image: Suspende of the sponsor Image: Suspende of the sponsor Y Image: Suspende of the sponsor Image: Suspende of the sponsor Y Image: Suspende of the sponsor Image: Suspende of the sponsor Y Image: Suspende of the sponsor Image: Suspende of the sponsor Image: Suspende of the sponsor <	Permissio ns delayed/d sponsorSuspende dy sponsorby sponsorSponsor DelaysImage: sponsor eniedImage: sponsor sponsorImage: sponsor sponsorImage: sponsor DelaysImage: sponsor sponsorImage: sponsor sponsorImage: sponsor sponsorImage: sponsor DelaysImage: sponsor sponsorImage: sponsor 	Permission scale delayed/d eniedSuspende by sponsor pelaysSponsor availabilit y issuesImage: scale operationImage: scale pelaysImage: scale pelaysImage: scale pelaysImage: scale operationImage: scale pelaysImage: scale pelaysImage: scale pelaysImage: scale pelaysImage: scale pelaysImage: scale omerationImage: scale pelaysImage: scale pelaysImage: scale pelaysImage: scale pelaysImage: scale pelaysImage: scale omerationImage: scale pelaysImage: scale pelaysImage: scale pelays </td <td>Permissio ns delayed/d eniedSuspende by sponsorSponsor Delaysavailabilit y issuespatients seenImage: Image: Im</td> <td>Permission schemed delayed/dSuspende sponsorSponsor Delaysavailabilit y issuespatients seenpatients consentedImage: sponsor eniedImage: sponsor sponsorYImage: sponsor sponsorImage: sponsor sponsorIm</td> <td>Permissio ns delayed/dSuspende by sponsorSponsor Delaysavailabilit y issuespatients seenDatients consentedContracti ng delaysImage: sponsor eniedImage: sponsor patientsImage: sponsor sponsorImage: sponsor sponsor<td>Permissions Suspende delayed/, disponsor by sponsor availability susues patients seen Contract. diseases Image: Supponde enied Image: Supponsor Y Image: Supponsor Imag</td><td>Permission ns delayed/ disponsor by sponsor Sponsor Delays availabilit y issues patients consented Contracti ng delays diseases Image: sponsor V Image: sponsor V Image: sponsor No Image: sponsor No Image: sponsor Image: sponsor Image: sponsor V Image: sponsor V Image: sponsor Image: sponsor</td></td>	Permissio ns delayed/d eniedSuspende by sponsorSponsor Delaysavailabilit y issuespatients seenImage: Image: Im	Permission schemed delayed/dSuspende sponsorSponsor Delaysavailabilit y issuespatients seenpatients consentedImage: sponsor eniedImage: sponsor sponsorYImage: sponsor sponsorImage: sponsor sponsorIm	Permissio ns delayed/dSuspende by sponsorSponsor Delaysavailabilit y issuespatients seenDatients consentedContracti ng delaysImage: sponsor eniedImage: sponsor patientsImage: sponsor sponsorImage: sponsor sponsor <td>Permissions Suspende delayed/, disponsor by sponsor availability susues patients seen Contract. diseases Image: Supponde enied Image: Supponsor Y Image: Supponsor Imag</td> <td>Permission ns delayed/ disponsor by sponsor Sponsor Delays availabilit y issues patients consented Contracti ng delays diseases Image: sponsor V Image: sponsor V Image: sponsor No Image: sponsor No Image: sponsor Image: sponsor Image: sponsor V Image: sponsor V Image: sponsor Image: sponsor</td>	Permissions Suspende delayed/, disponsor by sponsor availability susues patients seen Contract. diseases Image: Supponde enied Image: Supponsor Y Image: Supponsor Imag	Permission ns delayed/ disponsor by sponsor Sponsor Delays availabilit y issues patients consented Contracti ng delays diseases Image: sponsor V Image: sponsor V Image: sponsor No Image: sponsor No Image: sponsor Image: sponsor Image: sponsor V Image: sponsor V Image: sponsor

						Y	NHS Provid
	Y					Y	Sponsor
		Y		Y			NHS Provid
Y				Y			Sponsor
			Y				Neither
 Y			Y	Y			Sponsor
Y			Y	Y			Sponsor
Y			Y	Y			Sponsor
Y			Y	Y			Sponsor
Y				Y			Sponsor
		Image: Constraint of the second se	Image: select of the select	Image: second	Image: select	Image: select	Image: state stat

02/03/2018		Y			Y	Y		Sponsor
to participate								
30/10/2017								
Y		Y	Y					Sponsor
				Y			Y	Neither
06/02/2018					Y	Y		NHS Provid
27/10/2017								
24/44/2047								
24/11/2017		Y				Y		Sponsor
29/03/2018		Y		Y		Y		Sponsor
27/02/2018 Y					Y			NHS Provic
12/12/2017		Y				Y		Sponsor
12/12/2017		1				1		5001301
06/03/2018		Y			Y	Y		Sponsor
00/03/2018		T			¹	r		Sponsor

11/05/2018			Y		Y	Y		Sponsor
19/02/2018			Y		Y	Y		Sponsor
12/06/2018			Y		Y	Y		Sponsor
21/03/2018			Y	Y				Sponsor
20/06/2018			Y		Y	Y		Sponsor
			Y					Sponsor
16/05/2018								
03/05/2018					Y			Neither
			Y		Y	Y		Sponsor
	Y				Y			Neither
								Neither
								AL 11
	Y							Neither
16/02/2018								
10/12/2017	V						V	Noither
19/12/2017	ſ						Y	Neither

06/04/2018			Y		Y	Y			Sponsor
00/04/2010									5001301
ined site con	firmation								
	Y							Y	Neither
	-				Y			-	Neither
18/06/2018									
					Y				Neither
					Y				Neither
			Y			Y			Sponsor
14/06/2018					Y				Neither
ined site con	firmation								
ined site con	firmation								
ined site con	firmation								
			Y				Y		Spansor
04/04/2018			1				1		Sponsor
0.70.72020									
					Y				Neither
			Y						Sponsor
					1				

17/07/2017	Y						Sponsor
05/07/2017							
23/08/2017							
17/10/2017						Y	Neither
				Y			Neither
01/09/2017	Y						Sponsor
08/03/2018 Y	 Y Y						Sponsor Neither
08/03/2018	T						Neithei
	 Y			Y	Y		Sponsor
18/01/2018	Y		Y	Y			Sponsor
14/09/2017							
	Y				Y		Sponsor
16/01/2018	Y						Sponsor
24/11/2017	Y			Y	Y		Sponsor
24/11/2017							

17/01/2018			Y					Sponsor
16/10/2017								
					Y			Neither
					Y			Neither
			Y					Sponsor
07/09/2017							Y	Neither
ined site confirmation		Y						Sponsor
13/03/2018			Y			Y		Sponsor
03/05/2018								
22/06/2018								
	+							
								
16/10/2017			Y		Y	Y		Sponsor
	+				Y			Neither
	<u> </u>	1	1					

		Y					Sponsor
20/03/2018		Y		Y			Sponsor
				Y			Neither
42/07/2040					<u>, , , , , , , , , , , , , , , , , , , </u>		
12/07/2018		Y			Y		Sponsor
04/04/2018		Y		Y			Sponsor
		Y			Y		Sponsor
20/02/2018				Y			Neither
		Y					Sponsor
				Y			Neither

		Y		Y	Y		Sponsor
08/05/2018							
08/03/2018							
		Y					Sponsor
		Y			Y		Sponsor
		Y					Sponsor

		Y				Sponsor
10/07/2018						

 		 		-	